ניקסואה תארח את יום המשקיעים בניו יורק ב-8 ביולי 2026

צוות ההנהלה והדירקטוריון ידונו בביצוע המסחרי בארה"ב, באסטרטגיית הצמיחה ובעדיפויות המרכזיות

מונט-סן-גיבר, בלגיה – 23 ביוני 2026, GLOBE NEWSWIRE –

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המתמקדת בפיתוח פתרונות חדשניים לטיפול בדום נשימה חסימתי בשינה (OSA), הודיעה היום כי תארח יום משקיעים ואנליסטים ביום רביעי, 8 ביולי 2026, בניו יורק. האירוע יתקיים במשרדי בנק אוף אמריקה ויתקיים בין השעות 10:00 ל-12:30 בצהריים ET(16:00 עד 18:30 שעון CET).

Nyxoah to Host Investor Day in New York on July 8, 2026

Leadership team and Board will discuss the U.S. commercial execution, growth strategy and key priorities

Mont-Saint-Guibert, Belgium – June 23, 2026, GlobeNewswire –

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that it will host an Investor and Analyst Day on Wednesday, July 8, 2026, in New York. The event will be held at the offices of Bank of America and will run from 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET).

The event will be webcast live for those unable to attend in person, with a replay available shortly afterwards. Participants joining via the webcast will be able to ask questions during the event.

Event details

• Date: Wednesday,July 8, 2026
• Time: 10:00 AM to12:30 PM ET (16:00 to 18:30 CET)
• Location: Bank ofAmerica Tower at One Bryant Park, 1111 Avenue of the Americas, New York,NY
• Registration andwebcast access: the link will be posted in the Events sectionof Nyxoah’s investor website or by contacting [email protected].

Agenda highlights

Nyxoah’s leadership team, Board members, and external experts will discuss the Company’s commercial execution, growth strategy, and key priorities, including:

• Genio U.S. launchmomentum:
  • Review ofsecond-quarter commercial key performance indicators
  • Physicians’perspective on real-world U.S. experience with Genio
  • Market dynamicsshaping Obstructive Sleep Apnea
• Reimbursement:Assessment of the U.S. reimbursement landscape, presented together with JDLymon Group, an independent market access and reimbursement consultingfirm.
• Path toprofitability: Company’s framework for disciplined growth, capitalefficiency and operating leverage.

Featured participants

Scheduled participants include Nyxoah’s leadership team and board, joined by external clinical and reimbursement experts:

• Robert Taub,Chairman of the Board; Olivier Taelman, Chief Executive Officer; and theNyxoah executive team
• Andrew T. Huang,MD, FACS – Pasha Snoring & Sinus Center (Houston, TX); former Directorof Sleep Surgery, Baylor College of Medicine
• Vikas Jain, MD,FAASM, FAAFP, CPE – Dream Center for Sleep & Circadian Science(Frisco, TX)
• JD Lymon Group

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep-disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and Nasdaq in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE Mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contacts:

Nyxoah

John Landry, CFO

[email protected]

Rémi Renard, Head of Investor Relations & Corporate Communication

[email protected]

Attachment

• ENGLISH_Nyxoah to Host Investor Day

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire